August 24, 2016
Corium Announces Streamlined Bioequivalence Development Path for Transdermal CorplexTM Memantine
Second Alzheimer’s Candidate to Follow Shortened Clinical Timeline…
Corium Announces Streamlined Bioequivalence Development Path for Transdermal CorplexTM Memantine
Second Alzheimer’s Candidate to Follow Shortened Clinical Timeline…
Corium Reports Third Quarter Fiscal 2016 Finan ial Results and Recent Corporate Highlights
MENLO PARK, Calif. , Aug. 04, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third…